Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma’s Q2 2026 results show strong momentum across its portfolio, with total product revenue reaching EUR 315 million—up 105% year over year—driven by its TransCon offerings. YORVIPATH revenue climbed to EUR 252 million on steady new patient demand in the U.S. and expansion in more than 35 countries. SKYTROFA added EUR 55 million, while YUVIWEL delivered EUR 8 million in its first U.S. quarter of commercial availability. Operating profit was EUR 220 million (65% operating margin), and net profit totaled EUR 207 million, or EUR 2.83 per diluted share versus a net loss the prior year. The company ended June 30 with EUR 812 million in cash and set full-year operating cash flow guidance above EUR 500 million.